-

Incyte to Report First Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 28, 2026.

The schedule for the press release and conference call/webcast is as follows:

  • Q1 2026 Press Release: April 28, 2026 at 7:00 a.m. ET
  • Q1 2026 Conference Call: April 28, 2026 at 8:00 a.m. ET
  • Domestic Dial-In Number: 877-407-3042
  • International Dial-In Number: 201-389-0864
  • Conference ID Number: 13759527

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13759527.

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte®

Incyte is redefining what’s possible in biopharmaceutical innovation. Through deep scientific expertise and a relentless focus on patients, we have built an established portfolio of first-in-class medicines and an extensive portfolio of next-generation medicines across our key franchises: Hematology, Oncology and Inflammation and Autoimmunity.

To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X and Instagram.

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

Incyte

NASDAQ:INCY

Release Summary
1Q Alert
Release Versions

Contacts

Incyte Contacts
Media
media@incyte.com

Investors
ir@incyte.com

More News From Incyte

Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting...

Incyte Announces Executive Leadership Appointments

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Announces Executive Leadership Appointments...

Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting...
Back to Newsroom